210 related articles for article (PubMed ID: 35121903)
21. Combination anti-CXCR4 and anti-PD-1 immunotherapy provides survival benefit in glioblastoma through immune cell modulation of tumor microenvironment.
Wu A; Maxwell R; Xia Y; Cardarelli P; Oyasu M; Belcaid Z; Kim E; Hung A; Luksik AS; Garzon-Muvdi T; Jackson CM; Mathios D; Theodros D; Cogswell J; Brem H; Pardoll DM; Lim M
J Neurooncol; 2019 Jun; 143(2):241-249. PubMed ID: 31025274
[TBL] [Abstract][Full Text] [Related]
22. Combined immunotherapy with controlled interleukin-12 gene therapy and immune checkpoint blockade in recurrent glioblastoma: An open-label, multi-institutional phase I trial.
Chiocca EA; Gelb AB; Chen CC; Rao G; Reardon DA; Wen PY; Bi WL; Peruzzi P; Amidei C; Triggs D; Seften L; Park G; Grant J; Truman K; Buck JY; Hadar N; Demars N; Miao J; Estupinan T; Loewy J; Chadha K; Tringali J; Cooper L; Lukas RV
Neuro Oncol; 2022 Jun; 24(6):951-963. PubMed ID: 34850166
[TBL] [Abstract][Full Text] [Related]
23. Glioblastoma recurrence after cediranib therapy in patients: lack of "rebound" revascularization as mode of escape.
di Tomaso E; Snuderl M; Kamoun WS; Duda DG; Auluck PK; Fazlollahi L; Andronesi OC; Frosch MP; Wen PY; Plotkin SR; Hedley-Whyte ET; Sorensen AG; Batchelor TT; Jain RK
Cancer Res; 2011 Jan; 71(1):19-28. PubMed ID: 21199795
[TBL] [Abstract][Full Text] [Related]
24. Preclinical investigation of combined gene-mediated cytotoxic immunotherapy and immune checkpoint blockade in glioblastoma.
Speranza MC; Passaro C; Ricklefs F; Kasai K; Klein SR; Nakashima H; Kaufmann JK; Ahmed AK; Nowicki MO; Obi P; Bronisz A; Aguilar-Cordova E; Aguilar LK; Guzik BW; Breakefield X; Weissleder R; Freeman GJ; Reardon DA; Wen PY; Chiocca EA; Lawler SE
Neuro Oncol; 2018 Jan; 20(2):225-235. PubMed ID: 29016938
[TBL] [Abstract][Full Text] [Related]
25. Impact of CD4 T cells on intratumoral CD8 T-cell exhaustion and responsiveness to PD-1 blockade therapy in mouse brain tumors.
Khan SM; Desai R; Coxon A; Livingstone A; Dunn GP; Petti A; Johanns TM
J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36543376
[TBL] [Abstract][Full Text] [Related]
26. The current landscape of systemic therapy for recurrent glioblastoma: A systematic review of randomized-controlled trials.
Fazzari FGT; Rose F; Pauls M; Guay E; Ibrahim MFK; Basulaiman B; Tu M; Hutton B; Nicholas G; Ng TL
Crit Rev Oncol Hematol; 2022 Jan; 169():103540. PubMed ID: 34808376
[TBL] [Abstract][Full Text] [Related]
27. Urokinase-induced smooth muscle cell responses require distinct signaling pathways: a role for the epidermal growth factor receptor.
Nicholl SM; Roztocil E; Davies MG
J Vasc Surg; 2005 Apr; 41(4):672-81. PubMed ID: 15874933
[TBL] [Abstract][Full Text] [Related]
28. An experimental model of anti-PD-1 resistance exhibits activation of TGFß and Notch pathways and is sensitive to local mRNA immunotherapy.
Bernardo M; Tolstykh T; Zhang YA; Bangari DS; Cao H; Heyl KA; Lee JS; Malkova NV; Malley K; Marquez E; Pollard J; Qu H; Roberts E; Ryan S; Singh K; Sun F; Wang E; Bahjat K; Wiederschain D; Wagenaar TR
Oncoimmunology; 2021 Mar; 10(1):1881268. PubMed ID: 33796402
[TBL] [Abstract][Full Text] [Related]
29. Mechanistic Analysis of an Extracellular Signal-Regulated Kinase 2-Interacting Compound that Inhibits Mutant BRAF-Expressing Melanoma Cells by Inducing Oxidative Stress.
Martinez R; Huang W; Samadani R; Mackowiak B; Centola G; Chen L; Conlon IL; Hom K; Kane MA; Fletcher S; Shapiro P
J Pharmacol Exp Ther; 2021 Jan; 376(1):84-97. PubMed ID: 33109619
[TBL] [Abstract][Full Text] [Related]
30. Cancer cell-intrinsic expression of MHC II in lung cancer cell lines is actively restricted by MEK/ERK signaling and epigenetic mechanisms.
Neuwelt AJ; Kimball AK; Johnson AM; Arnold BW; Bullock BL; Kaspar RE; Kleczko EK; Kwak JW; Wu MH; Heasley LE; Doebele RC; Li HY; Nemenoff RA; Clambey ET
J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32312906
[TBL] [Abstract][Full Text] [Related]
31. Intranasal perillyl alcohol therapy improves survival of patients with recurrent glioblastoma harboring mutant variant for MTHFR rs1801133 polymorphism.
Faria GM; Soares IDP; D'Alincourt Salazar M; Amorim MR; Pessoa BL; da Fonseca CO; Quirico-Santos T
BMC Cancer; 2020 Apr; 20(1):294. PubMed ID: 32264844
[TBL] [Abstract][Full Text] [Related]
32. Protein Kinase CK2α Maintains Extracellular Signal-regulated Kinase (ERK) Activity in a CK2α Kinase-independent Manner to Promote Resistance to Inhibitors of RAF and MEK but Not ERK in BRAF Mutant Melanoma.
Zhou B; Ritt DA; Morrison DK; Der CJ; Cox AD
J Biol Chem; 2016 Aug; 291(34):17804-15. PubMed ID: 27226552
[TBL] [Abstract][Full Text] [Related]
33. ERK activation contributes to regulation of spontaneous contractile tone via superoxide anion in isolated rat aorta of angiotensin II-induced hypertension.
Ding L; Chapman A; Boyd R; Wang HD
Am J Physiol Heart Circ Physiol; 2007 Jun; 292(6):H2997-3005. PubMed ID: 17308007
[TBL] [Abstract][Full Text] [Related]
34. Mechanisms regulating the constitutive activation of the extracellular signal-regulated kinase (ERK) signaling pathway in ovarian cancer and the effect of ribonucleic acid interference for ERK1/2 on cancer cell proliferation.
Steinmetz R; Wagoner HA; Zeng P; Hammond JR; Hannon TS; Meyers JL; Pescovitz OH
Mol Endocrinol; 2004 Oct; 18(10):2570-82. PubMed ID: 15243131
[TBL] [Abstract][Full Text] [Related]
35. Phosphoproteomics of MAPK inhibition in BRAF-mutated cells and a role for the lethal synergism of dual BRAF and CK2 inhibition.
Parker R; Clifton-Bligh R; Molloy MP
Mol Cancer Ther; 2014 Jul; 13(7):1894-906. PubMed ID: 24825855
[TBL] [Abstract][Full Text] [Related]
36. RAF-Mutant Melanomas Differentially Depend on ERK2 Over ERK1 to Support Aberrant MAPK Pathway Activation and Cell Proliferation.
Crowe MS; Zavorotinskaya T; Voliva CF; Shirley MD; Wang Y; Ruddy DA; Rakiec DP; Engelman JA; Stuart DD; Freeman AK
Mol Cancer Res; 2021 Jun; 19(6):1063-1075. PubMed ID: 33707308
[TBL] [Abstract][Full Text] [Related]
37. Distinct Molecular Profiles and Immunotherapy Treatment Outcomes of V600E and V600K
Pires da Silva I; Wang KYX; Wilmott JS; Holst J; Carlino MS; Park JJ; Quek C; Wongchenko M; Yan Y; Mann G; Johnson DB; McQuade JL; Rai R; Kefford RF; Rizos H; Scolyer RA; Yang JYH; Long GV; Menzies AM
Clin Cancer Res; 2019 Feb; 25(4):1272-1279. PubMed ID: 30630828
[TBL] [Abstract][Full Text] [Related]
38. BRAF V600E and previously unidentified KRAS G12C mutations in odontogenic tumors may affect MAPK activation differently depending on tumor type.
Oh KY; Kim JH; Cho SD; Yoon HJ; Lee JI; Hong SD
Genes Chromosomes Cancer; 2022 Aug; 61(8):481-490. PubMed ID: 35353428
[TBL] [Abstract][Full Text] [Related]
39. Specificity of Phosphorylation Responses to Mitogen Activated Protein (MAP) Kinase Pathway Inhibitors in Melanoma Cells.
Basken J; Stuart SA; Kavran AJ; Lee T; Ebmeier CC; Old WM; Ahn NG
Mol Cell Proteomics; 2018 Apr; 17(4):550-564. PubMed ID: 29255136
[TBL] [Abstract][Full Text] [Related]
40. Radiation-induced c-Jun activation depends on MEK1-ERK1/2 signaling pathway in microglial cells.
Deng Z; Sui G; Rosa PM; Zhao W
PLoS One; 2012; 7(5):e36739. PubMed ID: 22606284
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
